29,146 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 29,146 shares of the company’s stock, valued at approximately $461,000. Connor Clark & Lunn Investment Management Ltd. owned 0.07% of Keros Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in Keros Therapeutics by 6.8% during the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock worth $42,146,000 after buying an additional 46,041 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Keros Therapeutics by 14.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock worth $15,105,000 after purchasing an additional 32,492 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Keros Therapeutics in the 4th quarter worth about $388,000. Barclays PLC increased its position in shares of Keros Therapeutics by 140.1% in the 3rd quarter. Barclays PLC now owns 60,014 shares of the company’s stock worth $3,484,000 after purchasing an additional 35,022 shares during the last quarter. Finally, Intech Investment Management LLC bought a new stake in shares of Keros Therapeutics in the 3rd quarter worth about $603,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Stock Down 1.9 %

Keros Therapeutics stock opened at $11.22 on Friday. The firm has a 50-day moving average price of $11.18 and a two-hundred day moving average price of $35.92. The firm has a market capitalization of $455.11 million, a price-to-earnings ratio of -2.15 and a beta of 1.39. Keros Therapeutics, Inc. has a 52-week low of $9.78 and a 52-week high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.22. The firm had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Research analysts expect that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. BTIG Research downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. William Blair downgraded shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 12th. Scotiabank dropped their target price on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a research report on Thursday, January 16th. Oppenheimer dropped their target price on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a research report on Thursday, January 16th. Finally, HC Wainwright decreased their price target on shares of Keros Therapeutics from $47.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, February 27th. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.33.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.